Patents by Inventor Martin Ebeling

Martin Ebeling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
    Publication number: 20240327837
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Application
    Filed: February 7, 2024
    Publication date: October 3, 2024
    Inventors: Congwei WANG, Christian WEILE, Martin EBELING, Lars JOENSON, Jonas VIKESAA, Ravi JAGASIA, Meiling LI
  • Oligonucleotides targeting RNA binding protein sites
    Patent number: 12084657
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 10, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Congwei Wang, Christian Weile, Martin Ebeling, Lars Joenson, Jonas Vikesaa, Ravi Jagasia, Meiling Li
  • GLUCOCEREBROSIDASE MUTANTS
    Publication number: 20220325265
    Abstract: The present invention provides variants of human ?-Glucocerebrosidase protein.
    Type: Application
    Filed: September 7, 2020
    Publication date: October 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Martin EBELING, Ravi JAGASIA, Nina Marion PFAHLER, Ralf THOMA
  • OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
    Publication number: 20220033818
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 3, 2022
    Inventors: Congwei WANG, Christian WEILE, Martin EBELING, Lars JOENSON, Jonas VIKESAA, Ravi JAGASIA, Meiling LI
  • Screening method
    Patent number: 10702530
    Abstract: The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: July 7, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Ebeling, Friedrich Metzger, Manaswini Sivaramakrishnan
  • SCREENING METHOD
    Publication number: 20180344737
    Abstract: The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 6, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Ebeling, Friedrich Metzger, Manaswini Sivaramakrishnan
  • Screening method
    Patent number: 9956223
    Abstract: The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: May 1, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Ebeling, Friedrich Metzger, Manaswini Sivaramakrishnan
  • SCREENING METHOD
    Publication number: 20180024115
    Abstract: The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.
    Type: Application
    Filed: February 19, 2016
    Publication date: January 25, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Ebeling, Friedrich Metzger, Manaswini Sivaramakrishnan
  • SCREENING METHOD
    Publication number: 20170241983
    Abstract: The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.
    Type: Application
    Filed: February 19, 2016
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Ebeling, Friedrich Metzger, Manaswini Sivaramakrishnan
  • MARKER PROTEIN FOR TYPE-2 DIABETES
    Publication number: 20120276561
    Abstract: The present invention provides a marker protein for the early detection of type II diabetes, antibodies directed to the marker protein and their use in a diagnostic method for type II diabetes and in drug development.
    Type: Application
    Filed: November 23, 2010
    Publication date: November 1, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Badi, Martin Ebeling, Hugues Matile, Cristiano Migliorini, Jacob Sabates Bellver, Thomas Schindler, Elena Sebokova, Haiyan Wang
  • Chimp trace amine associated receptors and polypeptides
    Publication number: 20060024787
    Abstract: The present invention provides a fingerprint sequence which is specific and selective for chimp trace amine associated receptors (TAAR) forming a subfamily of G protein coupled receptors. The invention also provides the novel chimp polypeptides identified as members of this family, nucleic acids encoding said polypeptides, and vectors and host cells comprising the novel family members. In addition, the invention provides methods of identifying chimp TAARs.
    Type: Application
    Filed: July 5, 2005
    Publication date: February 2, 2006
    Inventors: Martin Ebeling, Marius Hoener, Lothar Lindemann
  • Human trace amine associated receptors
    Publication number: 20060009441
    Abstract: The present invention provides a fingerprint sequence which is specific and selective for trace amine associated receptors (TAAR) forming a subfamily of G protein coupled receptors. The invention also provides the novel human polypeptides identified as members of this family, nucleic acids encoding said polypeptides, and vectors and host cells comprising the novel family members. In addition, the invention provides methods of identifying TAARs.
    Type: Application
    Filed: July 5, 2005
    Publication date: January 12, 2006
    Inventors: Martin Ebeling, Marius Hoener, Lothar Lindemann
  • Mouse trace amine associated receptors and polypeptides
    Publication number: 20060008880
    Abstract: The present invention provides a fingerprint sequence which is specific and selective for trace amine associated receptors (TAAR) forming a subfamily of G protein coupled receptors. The invention also provides the novel mouse polypeptides identified as members of this family, nucleic acids encoding said polypeptides, and vectors and host cells comprising the novel family members. In addition, the invention provides methods of identifying TAARs.
    Type: Application
    Filed: July 5, 2005
    Publication date: January 12, 2006
    Inventors: Martin Ebeling, Marius Hoener, Lothar Lindemann
  • PPARdelta assay
    Publication number: 20050233361
    Abstract: The present invention relates to ANGPTL4 as biomarkers for PPARdelta activity, and to methods of diagnosing a disease linked to dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, methods of monitoring the treatment of patients suffering from a disease linked to dysregulation of PPARdelta activity and methods of identifying compounds which modulate PPARdelta activity.
    Type: Application
    Filed: March 30, 2005
    Publication date: October 20, 2005
    Inventors: Roger Clerc, Martin Ebeling, Christophe Gardes, Markus Meyer, Matthew Wright
  • Osteolevin gene polymorphisms
    Publication number: 20040132021
    Abstract: The present inventon relates generally to genetic polymorphisms in the Van Buchem-scierosteosis disease region. In particular, the present invention relates to genetic polymorphisms in the Van Buchem-sclerosteosis disease region that are associated with disorders resulting in either net excess bone formation or insufficient bone formation in humans. Furthermore, isolated nucleic acid molecules encoding human osteolevin are provided. Osteolevin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same.
    Type: Application
    Filed: September 29, 2003
    Publication date: July 8, 2004
    Inventors: Wendy Balemans, Martin Ebeling, Dorothee Foernzler, Neela Patel, Wim Van Hul